Re:Search Institution Members

Non-Former Members Country
Aberystwyth UniversityUnited Kingdom
Addis Ababa University (AAU)Ethiopia
Africa Fighting Malaria (AFM)South Africa
African Institute of Biomedical Science and Technology (AiBST)Zimbabwe
AHMADU BELLO UNIVERSITY ZARIANigeria
Anchor University Lagos (AUL)Nigeria
Armauer Hansen Research Institute (AHRI)Ethiopia
Association of University Technology Managers (AUTM)United States of America
Bandung Institute of Technology (ITB)Indonesia
Bibliotheca AlexandrinaEgypt
Biomedical Center of the Central University of Ecuador (UCE)Ecuador
Biomedical Research Institute (BRI)United States of America
Biotechnology Innovation Organization (BIO)United States of America
Brazilian Biosciences National Laboratory (LNBio)Brazil
Burnet InstituteAustralia
California Institute of Technology (Caltech)United States of America
Case Western Reserve University (CWRU)United States of America
Center for Infectious Disease Research (CIDR)United States of America
Center for Molecular Dynamics Nepal (CMDN)Nepal
Centre for Plant Medicine Research (CPMR)Ghana
Centre Pasteur du Cameroun (CPC)Cameroon
Congolese Foundation for Medical Research (FCRM)Congo
Council on Health Research for Development (COHRED)Switzerland
Developing World HealthUnited Kingdom
Drugs for Neglected Diseases initiative (DNDi)Switzerland
Eijkman Institute for Molecular Biology (EIMB)Indonesia
Eisai Co., Ltd.Japan
Emory UniversityUnited States of America
European CommissionBelgium
Foundation for Innovative New Diagnostics (FIND)Switzerland
Foundation for Neglected Disease Research (FNDR)India
GALVmedUnited Kingdom
GlaxoSmithKline (GSK)United Kingdom
Global Healthcare Innovation Alliance Accelerator (GHIAA)United States of America
Griffith Institute for Drug Discovery (GRIDD)Australia
Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of SciencesChina
Health Sciences Research Institute (IRSS)Burkina Faso
Icahn School of Medicine at Mount Sinai (ISMMS)United States of America
Indian Council of Medical Research (ICMR)India
Infectious Disease Research Institute (IDRI)United States of America
Institut PasteurFrance
Institut Pasteur de Madagascar (IPM)Madagascar
Institut Pasteur de MontevideoUruguay
Institut Pasteur de TunisTunisia
Institut Pasteur KoreaRepublic of Korea
Institute of Molecular and Cellular Biology of Rosario (IBR)Argentina
Institute of Science and Technology (INSTech)Burkina Faso
International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)Bangladesh
International Centre for Genetic Engineering and Biotechnology (ICGEB)India
International Federation of Intellectual Property Attorneys (FICPI)Switzerland
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)Switzerland
International Hospital Federation (IHF)Switzerland
International Vaccine Institute (IVI)Republic of Korea
James Cook University (JCU)Australia
Johnson & JohnsonUnited States of America
Jomo Kenyatta University of Agriculture and Technology (JKUAT)Kenya
Kenya Agricultural & Livestock Research Organisation (KALRO)Kenya
Kenya Medical Research Institute (KEMRI)Kenya
Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR)Ghana
Licensing Executives Society International (LESI)United States of America
LifeArcUnited Kingdom
Liverpool School of Tropical Medicine (LSTM)United Kingdom
London School of Hygiene & Tropical MedicineUnited Kingdom
Mahidol UniversityThailand
Makerere UniversityUganda
Malaria ConsortiumUnited Kingdom
Massachusetts General Hospital (MGH)United States of America
Massachusetts Institute of Technology (MIT)United States of America
McGill UniversityCanada
McMaster UniversityCanada
Medical College of Wisconsin (MCW)United States of America
Medical Research Institute - Alexandria UniversityEgypt
Medicines for Malaria Venture (MMV)Switzerland
Merck KGaA (Known as Merck KGaA, Darmstadt, Germany in the United States of America and Canada)Germany
Monash UniversityAustralia
MSD (Known as Merck & Co., Inc. in the United States of America and Canada)United States of America
Murdoch Children's Research Institute (MCRI)Australia
National Center for Genetic Engineering and Biotechnology (BIOTEC)Thailand
National Hansen’s Disease Program (NHDP)United States of America
National Institute for Medical Research (NIMR)United Republic of Tanzania
National Institute of Immunology (NII)India
National Institute of Industrial Property (INPI)Brazil
National Institute of Parasitic Diseases (NIPD), Chinese Center for Disease Control and PreventionChina
National Institutes of Health (NIH)United States of America
National University of Singapore (NUS)Singapore
Nigerian Institute of Medical Research (NIMR)Nigeria
Noguchi Memorial Institute for Medical Research (NMIMR)Ghana
Northeastern UniversityUnited States of America
Novartis AGSwitzerland
Operation ASHAIndia
Oswaldo Cruz Foundation (Fiocruz)Brazil
Papua New Guinea Institute of Medical Research (PNGIMR)Papua New Guinea
PATHUnited States of America
Pfizer Inc.United States of America
Public Health Institute (PHI)Sudan
Public Health Research Institute (PHRI)United States of America
Public Interest Intellectual Property Advisors (PIIPA)United States of America
Puerto Rico Science, Technology & Research TrustUnited States of America
Research Institute for Tropical Medicine (RITM)Philippines
Sabin Vaccine InstituteUnited States of America
SalvensisUnited Kingdom
Seattle Children's Research Institute (SCRI)United States of America
Social Medicine Institute (IMS), Rio de Janeiro State University (IMS/UERJ)Brazil
South African Medical Research Council (SAMRC)South Africa
Stanford UniversityUnited States of America
Structural Genomics Consortium (SGC)Canada
Swiss Tropical and Public Health Institute (Swiss TPH)Switzerland
Takeda Pharmaceutical Company LimitedJapan
Tech Transfer Summit Ltd. (TTS)United Kingdom
Texas Children’s Hospital Center for Vaccine Development (Texas Children's CVD)United States of America
The Federal University of Health Sciences of Porto AlegreBrazil
The George Washington University (GW)United States of America
Theodor Bilharz Research Institute (TBRI)Egypt
Tulane UniversityUnited States of America
United States Patent and Trademark Office (USPTO)United States of America
Universidad de AntioquiaColombia
Universidad Peruana Cayetano HerediaPeru
Université Paris-SaclayFrance
University Cheikh Anta Diop of Dakar (UCAD)Senegal
University of BamakoMali
University of BamendaCameroon
University of British Columbia (UBC)Canada
University of BueaCameroon
University of CalgaryCanada
University of California, Berkeley (UCB)United States of America
University of California, San Diego (UCSD)United States of America
University of California, San Francisco (UCSF)United States of America
University of Campinas (Unicamp)Brazil
University of Cape CoastGhana
University of DschangCameroon
University of DundeeUnited Kingdom
University of EdinburghUnited Kingdom
University of Florida (UF)United States of America
University of Georgia (UGA)United States of America
University of GhanaGhana
University of IbadanNigeria
University of KansasUnited States of America
University of Lagos (Unilag)Nigeria
University of MauritiusMauritius
University of MelbourneAustralia
University of Nebraska Medical CenterUnited States of America
University of New South Wales (UNSW)Australia
University of Papua New Guinea (UPNG) School of Medicine and Health SciencesPapua New Guinea
University of Puerto RicoUnited States of America
University of Rwanda (UR)Rwanda
University of São PauloBrazil
University of South CarolinaUnited States of America
University of South Florida (USF)United States of America
University of Texas (UT) Southwestern Medical CenterUnited States of America
University of the Republic of UruguayUruguay
University of TokyoJapan
University of Toronto (U of T)Canada
University of Vermont (UVM)United States of America
University of Washington (UW)United States of America
University of Yaoundé ICameroon
University of ZambiaZambia
Usmanu Danfodiyo University, Sokoto (UDUS)Nigeria
Walter and Eliza Hall Institute of Medical Research (WEHI)Australia
Walter Reed Army Institute of Research (WRAIR)United States of America
Washington University in St. Louis (WUSTL)United States of America
Former Members Country
60P Pharmaceuticals (Former Member)United States of America
Alnylam (Former Member)Germany
Anacor (Former member)United States of America
AstraZeneca (Former Member)United Kingdom
Center for World Health Medicine (Former Member)United States of America
iThemba (Former member)South Africa
Kineta (Former member)United States of America
Sanofi (Former Member)France
Title Start date Diseases Members
Testing peptides for activity against Leishmania 2014 Leishmaniasis
  • Stanford University
  • University of California San Diego (UCSD)
Repurposing compounds for Neurocysticercosis drug discovery 2014 Cysticercosis/Taeniasis
  • University of California San Diego (UCSD)
  • University of California San Francisco (UCSF)
  • National Institutes of Health (NIH)
WIPO Fellowship - Research sabbatical in urogenital schistosomiasis 2013 Schistosomiasis
  • Stanford University
  • Theodor Bilharz Research Institute (TBRI)
Using the Foldscope to diagnose Malaria 2013 Malaria
  • Stanford University
  • University of Lagos (Unilag)
Screening Nature Bank Isolates for Activity Against Parasitic Helminths 2014 Soil-transmitted helminthiasis (STH),Schistosomiasis
  • Griffith Institute for Drug Discovery (GRIDD)
  • Swiss Tropical and Public Health Institute (Swiss TPH)
Hosting and training in use of PCR to identify antimalarial resistance 2014 Malaria
  • National Institute of Parasitic Diseases (NIPD)
  • Chinese Center for Disease Control and Prevention
  • University of Lagos (Unilag)
Testing a diagnostic for Schistosoma japonicum against S. mansoni and S. haematobium 2014 Schistosomiasis
  • National Institute of Parasitic Diseases (NIPD)
  • Chinese Center for Disease Control and Prevention
  • University of Ibadan
Multiplexed RT-PCR for Diagnosing Febrile Illnesses in Cameroon 2014 Malaria,Dengue
  • Stanford University
  • Centre Pasteur du Cameroun (CPC)
Hosting and assay optimization for undifferentiated febrile illnesses 2014 Malaria,Dengue
  • Stanford University
  • University of Lagos (Unilag)
Repurposing Avermectins for Buruli Ulcer treatment 2014 Buruli ulcer
  • Swiss Tropical and Public Health Institute (Swiss TPH)
  • University of British Columbia (UBC)
Concentrating soil-transmitted Helminths from soil and sewage samples 2014 Soil-transmitted helminthiasis (STH)
  • McMaster University
  • University of South Florida (USF)
Assessing Host-Directed Activators for Liver-Stage Malaria 2015 Malaria
  • Center for Infectious Disease Research (CIDR)
  • Pfizer Inc.
Virtual Screen of Phosphodiesterase (PDE) inhibitors against mycobacterium tuberculosis 2014 Tuberculosis
  • Northeastern University
  • Washington University in St. Louis (WUSTL)
  • Center for World Health Medicine (Former Member)
Screening Nature Bank Isolates for Activity Against Mycobacterium Tuberculosis 2013 Tuberculosis
  • Griffith Institute for Drug Discovery (GRIDD)
  • AstraZeneca (Former Member)
Screening Cysteine Protease inhibitors for NTD drug discovery 2012 Soil-transmitted helminthiasis (STH),Schistosomiasis,Malaria,Chagas disease,Human African trypanosomiasis (HAT)
  • University of California San Francisco (UCSF)
  • AstraZeneca (Former Member)
Screening Mycobacterium tuberculosis hits against Mycobacterium ulcerans 2013 Buruli ulcer
  • Swiss Tropical and Public Health Institute (Swiss TPH)
  • AstraZeneca (Former Member)
Repurposing Cyp51 inhibitors for Chagas disease drug discovery 2012 Chagas disease
  • University of California San Francisco (UCSF)
  • AstraZeneca (Former Member)
Data sharing to advance drug development for Kinetoplastid diseases and Malaria 2015 Malaria,Chagas disease,Leishmaniasis,Human African trypanosomiasis (HAT)
  • Northeastern University
  • Swiss Tropical and Public Health Institute (Swiss TPH)
  • Drugs for Neglected Diseases initiative (DNDi)
Re-purposing compounds for Chagas disease, Leishmaniasis, Lymphatic Filariasis, and Schistosomiasis drug discovery 2015 Lymphatic filariasis,Schistosomiasis,Chagas disease,Leishmaniasis
  • University of California San Diego (UCSD)
  • Eisai Co., Ltd.
Repurposing nicotinic Acetylcholine receptor agonists for Hookworm 2016 Soil-transmitted helminthiasis (STH)
  • Swiss Tropical and Public Health Institute (Swiss TPH)
  • Pfizer Inc.
Repurposing cicotinic Acetylcholine receptor agonists for STH 2016 Soil-transmitted helminthiasis (STH)
  • Swiss Tropical and Public Health Institute (Swiss TPH)
  • Johnson & Johnson
Sharing of MetAP-1 Inhibitor data to inform Tuberculosis drug development strategies 2012 Tuberculosis
  • GlaxoSmithKline (GSK)
  • Center for World Health Medicine (Former Member)
Advice on Phosphodiesterase (PDE) Inhibitor Optimization for HAT Drug Development 2013 Human African trypanosomiasis (HAT)
  • Northeastern University
  • Eisai Co., Ltd.
Screening compounds for Malaria drug discovery 2013 Malaria
  • University of Dundee
  • Eisai Co., Ltd.
Repurposing compounds for Malaria drug discovery 2013 Malaria
  • University of Dundee
  • Eisai Co., Ltd.
Profiling of transmission-blocking compounds for Malaria treatment 2012 Malaria
  • University of Washington (UW)
  • GlaxoSmithKline (GSK)
Screening compounds against the Wolbachia Endosymbiont of filarial nematodes 2013 Lymphatic filariasis,Onchocerciasis
  • Liverpool School of Tropical Medicine (LSTM)
  • AstraZeneca (Former Member)
Repurposing GSK-3 Inhibitors for Kinetoplastids 2012 Chagas disease,Leishmaniasis,Human African trypanosomiasis (HAT)
  • University of Dundee
  • AstraZeneca (Former Member)
Assessing Activity of Nucleoside Analogs against RNA and DNA Viruses 2012 Dengue
  • Emory University
  • National Institutes of Health (NIH)
Expertise-sharing for Tuberculosis diagnostic development 2014 Tuberculosis
  • California Institute of Technology (Caltech)
  • PATH
In Vitro ADME Support and Computational Modeling for HAT Drug Discovery 2013 Human African trypanosomiasis (HAT)
  • Northeastern University
  • AstraZeneca (Former Member)
Providing Modipafant investigator’s brochure for Dengue drug development 2013 Dengue
  • Pfizer Inc.
  • 60P Pharmaceuticals (Former Member)
Screening Polo-like Kinase Inhibitors for Schistosomiasis Drug Discovery 2013 Schistosomiasis
  • University of California San Francisco (UCSF)
  • GlaxoSmithKline (GSK)
Designing optimized siRNAs for gene silencing in Schistosoma mansoni 2013 Schistosomiasis
  • Aberystwyth University
  • Alnylam (Former Member)
Temperature control system to support PCR diagnostic for Malaria 2014 Malaria
  • University of Calgary
  • PATH
NINA Heater for Reverse Transcription LAMP Assay to Detect Malaria 2015 Malaria
  • Centre Pasteur du Cameroun (CPC)
  • PATH
Screening Xanthine analogs for Chagas disease drug discovery 2015 Chagas disease
  • University of California San Diego (UCSD)
  • GlaxoSmithKline (GSK)
Repurposing compounds for Tuberculosis drug discovery 2014 Tuberculosis
  • Infectious Disease Research Institute (IDRI)
  • GlaxoSmithKline (GSK)
Sharing anti-Malarial compounds to assess liver-stage Malaria screening system 2014 Malaria
  • Massachusetts Institute of Technology (MIT)
  • GlaxoSmithKline (GSK)
Profiling Multi-Kinase Inhibitors for Malaria Drug Discovery 2012 Malaria
  • University of Washington (UW)
  • GlaxoSmithKline (GSK)
Sharing of Kinase inhibitors for testing against liver stage Malaria parasites 2014 Malaria
  • National Institute of Immunology (NII)
  • GlaxoSmithKline (GSK)
WIPO Fellowship - Hosting and training on malaria diagnostics development 2013 Malaria
  • University of Lagos (Unilag)
  • Novartis AG
Testing JAK-3 Kinase inhibitor in cerebral Malaria animal model 2013 Malaria
  • McGill University
  • Pfizer Inc.
Formulation advice for a topically-administered anti-Leishmania compound 2013 Leishmaniasis
  • Stanford University
  • AstraZeneca (Former Member)
Repurposing preclinical and clinical candidates for Malaria 2012 Malaria
  • Liverpool School of Tropical Medicine (LSTM)
  • AstraZeneca (Former Member)
Using C. Elegans to search for anti-helminth compounds 2013 Soil-transmitted helminthiasis (STH)
  • McGill University
  • AstraZeneca (Former Member)
Compound Repurposing for Human African Trypanosomiasis Drug Discovery 2014 Human African trypanosomiasis (HAT)
  • Center for Infectious Disease Research (CIDR)
  • GlaxoSmithKline (GSK)
Using C. Elegans mutants to elucidate Anthelmintic compounds’ mechanisms of action 2013 Soil-transmitted helminthiasis (STH),Onchocerciasis
  • McGill University
  • Drugs for Neglected Diseases initiative (DNDi)
  • AstraZeneca (Former Member)
Screening Boron-based compounds against Mycobacterium tuberculosis drug targets 2012 Tuberculosis
  • AstraZeneca (Former Member)
  • Anacor (Former member)
Screening inhibitors against Onchocerca microfilariae and macrofilariae 2014 Onchocerciasis
  • Aberystwyth University
  • University of Buea
siRNAs targeting a hepatocyte receptor on P. falciparum invasion of hepatocytes in vivo 2016 Malaria
  • Center for Infectious Disease Research (CIDR)
  • Alnylam (Former Member)
Gene validation studies via RNAi for drug discovery efforts against Schistosoma mansoni 2017 Schistosomiasis
  • Oswaldo Cruz Foundation (Fiocruz)
  • Alnylam (Former Member)
Optimized siRNAs to assess regulation of host hepatocyte genes during liver-stage malaria 2014 Malaria
  • Northeastern University
  • National Institute of Immunology (NII)
  • Alnylam (Former Member)
Optimized siRNAs against a host protein expressed in macrophages during M. Tuberculosis infection 2014 Tuberculosis
  • Tulane University
  • Alnylam (Former Member)
Knowledge, data, and structures of inhibitors for product development against Shigella 2012 Tuberculosis
  • AstraZeneca (Former Member)
  • Anacor (Former member)
Express and purify a recombinant Schistosoma protein to assess in vitro immune response to this protein in human cells 2015 Schistosomiasis
  • Biomedical Research Institute (BRI)
  • University Cheikh Anta Diop of Dakar (UCAD)
Computational and predictive chemistry know-how and support to improve compound characteristics for tuberculosis drug candidates 2012 Tuberculosis
  • AstraZeneca (Former Member)
  • iThemba (Former member)
Share of Genomic DNA from S. mansoni and parasite’s intermediate snail host, B. pfeifferi 2016 Schistosomiasis
  • Biomedical Research Institute (BRI)
  • Nigerian Institute of Medical Research (NIMR)
Share of natural product extracts to screen against Plasmodium parasites in vitro. 2016 Malaria
  • Centre Pasteur du Cameroun (CPC)
  • Nigerian Institute of Medical Research (NIMR)
Knowledge exchange on parameters to consider during adjuvant design 2013 Unknown disease
  • Infectious Disease Research Institute (IDRI)
  • Eisai Co., Ltd.
Share of phosphodiesterase (PDE) V inhibitors and calcium channel blockers to screen the compounds for activity against intracellular M. tuberculosis 2018 Tuberculosis
  • Infectious Disease Research Institute (IDRI)
  • Eisai Co., Ltd.
Knowledge exchange on formulation of anti-fungal compound 2013 Unknown disease
  • Eisai Co., Ltd.
  • University of Kansas
Share of inhibitors to test against cerebral Malaria 2014 Malaria
  • Liverpool School of Tropical Medicine (LSTM)
  • Eisai Co., Ltd.
Share classes of inhibitors including kinase inhibitors and calcium channel blockers to screen for activity against Onchocerca adult worm 2018 Onchocerciasis
  • University of Buea
  • Eisai Co., Ltd.
Share of inhibitors to screen against Leishmania, T. cruzi, S. mansoni, and Brugia 2015 Chagas disease,Leishmaniasis
  • University of California San Diego (UCSD)
  • Eisai Co., Ltd.
Share of two targeted sets of inhibitors to screen against S. mansoni 2017 Schistosomiasis
  • University of California San Diego (UCSD)
  • Eisai Co., Ltd.
Share of targeted set of inhibitors and their structures to test against Leishmania spp. and T. cruzi 2017 Chagas disease,Leishmaniasis
  • University of California San Diego (UCSD)
  • Eisai Co., Ltd.
Advice regarding a Polio diagnostic 2014 Unknown disease
  • Emory University
  • California Institute of Technology (Caltech)
Share of in vivo data to license a virus strain and provide its animal model set up guidance 2014 Unknown disease
  • Emory University
  • Kineta (Former member)
Measure the plasmablast response induced in human subjects following administration of two candidate dengue vaccines 2014 Dengue
  • Emory University
  • Walter Reed Army Institute of Research (WRAIR)
  • GlaxoSmithKline (GSK)
Share of resistant TB strains to see efficiency of a promising drug 2017 Tuberculosis
  • Institut Pasteur Korea
  • Foundation for Innovative New Diagnostics (FIND)
Share of targeted set of compounds from its TCAKS to assess their effects on T. cruzi 2015 Chagas disease
  • Oswaldo Cruz Foundation (Fiocruz)
  • GlaxoSmithKline (GSK)
Share of kinase inhibitors to study M. tuberculosis metabolic pathways 2013 Malaria
  • National Institute of Immunology (NII)
  • GlaxoSmithKline (GSK)
Share of set of kinase inhibitors to screen against liver-stage malaria parasites 2014 Malaria
  • National Institute of Immunology (NII)
  • GlaxoSmithKline (GSK)
Share of set of compounds with different anti-malarial properties to test effects on erythrocyte deformability during Plasmodium infection 2015 Malaria
  • University of British Columbia (UBC)
  • GlaxoSmithKline (GSK)
Share of small molecules which previously demonstrated to have promising activity against M. tuberculosis-infected macrophages in vitro 2017 Tuberculosis
  • University of California
  • Berkeley (UCB)
  • GlaxoSmithKline (GSK)
Expertise and advice to improve the solubility and bioavailability and anti-tuberculosis coumponds 2013 Tuberculosis
  • Infectious Disease Research Institute (IDRI)
  • South African Medical Research Council (SAMRC)
Share of Jump-stARter library to screen against Mycobacterium tuberculosis in vitro under conditions that mimic important aspects of human pathogenesis 2017 Tuberculosis
  • National Institutes of Health (NIH)
  • Johnson & Johnson
Share of Jump-stARter library to screen the library against C. elegans to identify inhibitors of a unique metabolic pathway found in parasitic worms. 2017 Soil-transmitted helminthiasis (STH)
  • University of Toronto (U of T)
  • Johnson & Johnson
Share of Jump-stARter library to screen against P. falciparum in vitro 2016 Malaria
  • Walter and Eliza Hall Institute of Medical Research (WEHI)
  • Johnson & Johnson
Share of Jump-stARter library to screen against a Mycobacterium tuberculosis enzyme 2017 Tuberculosis
  • Washington University in St. Louis (WUSTL)
  • Johnson & Johnson
Exploration of grant opportunities, exchange between students, collaborative lab projects 2013 Unknown disease
  • Northeastern University
  • Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR)
Share of stool samples to support the researchers’ helminth diagnostic product development and testing 2012 Soil-transmitted helminthiasis (STH)
  • Stanford University
  • Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR)
Develop formulations of antiviral 2014 Dengue
  • University of Kansas
  • Kineta (Former member)
Share of stool and plasma samples from Trichuris-infected children in Ecuador 2014 Soil-transmitted helminthiasis (STH)
  • University of California San Francisco (UCSF)
  • Liverpool School of Tropical Medicine (LSTM)
Share of frozen cell extracts of Cryptosporidium infected cells to identify potential antigens for use in a vaccine 2014 Unknown disease
  • McGill University
  • University of British Columbia (UBC)
Share of frozen cell extracts of T. cruzi infected cell to identify potential antigens for use in a vaccine 2014 Chagas disease
  • McGill University
  • University of British Columbia (UBC)
Microfluidic diagnostic to detect bacteria in banked milk 2015 Unknown disease
  • McMaster University
  • PATH
Library of phosphoinositide-3-kinase (PI3K) inhibitors to screen against various NTDs 2017 Chagas disease,Human African trypanosomiasis (HAT)
  • University of California San Diego (UCSD)
  • Merck KGaA (Known as Merck KGaA, Darmstadt, Germany in the United States of America and Canada)
Highly potent Hsp90 inhibitors to screen against Onchocerca worms 2015 Onchocerciasis
  • University of Buea
  • Merck KGaA (Known as Merck KGaA, Darmstadt, Germany in the United States of America and Canada)
Membrane-bound protein purification expertise for Tuberculosis 2013 Tuberculosis
  • Emory University
  • MSD (Known as Merck & Co. Inc. in the United States of America and Canada)
HMG-CoA reductase inhibitors (statins) to screen against schistosomal worms 2012 Schistosomiasis
  • Center for Infectious Disease Research (CIDR)
  • University of California San Diego (UCSD)
  • University of California San Francisco (UCSF)
  • MSD (Known as Merck & Co. Inc. in the United States of America and Canada)
Set of compounds to screen against Plasmodium 2014 Malaria
  • Walter and Eliza Hall Institute of Medical Research (WEHI)
  • MSD (Known as Merck & Co. Inc. in the United States of America and Canada)
Natural product extracts to screen against M. tuberculosis 2013 Tuberculosis
  • Infectious Disease Research Institute (IDRI)
  • National Institutes of Health (NIH)
Natural products to test against kinetoplastids 2015 Chagas disease,Leishmaniasis,Human African trypanosomiasis (HAT)
  • Institut Pasteur Korea
  • National Institutes of Health (NIH)
Use of preclinical services program to increase thermostability of investigational rabies vaccine 2015 Rabies
  • Institut Pasteur de Tunis
  • National Institutes of Health (NIH)
K13 gene of Plasmodium falciparum parasites found within malaria patient blood samples 2017 Malaria
  • Centre Pasteur du Cameroun (CPC)
  • National Institute of Parasitic Diseases (NIPD)
  • Chinese Center for Disease Control and Prevention
Sequence of K13 gene of a set of malaria parasites obtained from Senegalese malaria patients 2016 Malaria
  • University Cheikh Anta Diop of Dakar (UCAD)
  • National Institute of Parasitic Diseases (NIPD)
  • Chinese Center for Disease Control and Prevention
Identify potential Schistosoma mansoni and S. haematobium antigens for rapid diagnostic 2016 Schistosomiasis
  • National Institute of Parasitic Diseases (NIPD)
  • Chinese Center for Disease Control and Prevention
  • University of Ibadan
Polyclonal anti-dengue antibody 2013 Dengue
  • McMaster University
  • Novartis AG
Co-development of a novel onchocerciasis diagnostic 2012 Onchocerciasis
  • Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR)
  • PATH
Compounds to evaluate in a rat diarrhea model 2013 Unknown disease
  • Pfizer Inc.
  • Center for World Health Medicine (Former Member)
Documentation and expertise on diarrheal diseases 2013 Unknown disease
  • Pfizer Inc.
  • PATH
Inhibitor to test in an animal model of diarrhea 2014 Unknown disease
  • Pfizer Inc.
  • PATH
  • University of Vermont (UVM)
Compounds to evaluate in a rat diarrhea model 2013 Unknown disease
  • Sanofi (Former Member)
  • Center for World Health Medicine (Former Member)
DNA and primers to test in a microfluidics instrument 2014 Dengue
  • Stanford University
  • California Institute of Technology (Caltech)
Paper microscopes used to test samples for helminth eggs 2016 Soil-transmitted helminthiasis (STH)
  • Stanford University
  • University of South Florida (USF)
Use of microneedle patch technology to administer a protein antigen-based, transmission-blocking malaria vaccine 2017 Malaria
  • National Institutes of Health (NIH)
  • Takeda Pharmaceutical Company Limited
Targeted set of compounds to screen against M. tuberculosis residing within macrophages 2016 Tuberculosis
  • University of British Columbia (UBC)
  • Takeda Pharmaceutical Company Limited
Targeted set of compounds to screen against Schistosoma mansoni in vitro 2016 Schistosomiasis
  • University of California San Diego (UCSD)
  • Takeda Pharmaceutical Company Limited
Set of preclinical/clinical-stage compounds to screen against B. pahangi 2017 Lymphatic filariasis
  • University of California San Francisco (UCSF)
  • Takeda Pharmaceutical Company Limited
Share of blood samples from malaria patients with varying levels of parasitemia for diagnostic development 2015 Malaria
  • McGill University
  • University of Lagos (Unilag)
Dried blood spot sampling (DBSS) and next generation sequencing of Plasmodium falciparum in malaria patients in Nigeria 2014 Malaria
  • University of Lagos (Unilag)
  • Novartis AG
Antibodies against Chagas disease host biomarkers for diagnostic development 2014 Chagas disease
  • McGill University
  • University of British Columbia (UBC)
Activity-guided fractionation on natural product extracts that have anti-onchocercal activities. 2014 Onchocerciasis
  • University of British Columbia (UBC)
  • University of Buea
Elucidate the structures of natural products that previously demonstrated to have anti-malarial or anti-tuberculosis activities 2014 Malaria,Tuberculosis
  • University of British Columbia (UBC)
  • University of Ibadan
Antibody against a human host protein to examine the effect of reducing the level of the host protein on the severity of malaria 2015 Malaria
  • University of British Columbia (UBC)
  • University of Lagos (Unilag)
Identification of biomarkers for a malaria diagnostic 2015 Malaria
  • University of British Columbia (UBC)
  • University of Lagos (Unilag)
Antibodies against the proteins assessed for their ability to block P. vivax entry into red blood cells 2015 Malaria
  • University of British Columbia (UBC)
  • Walter and Eliza Hall Institute of Medical Research (WEHI)
Set of T. cruzi antigens to incorporate into a silicon chip-based Chagas disease diagnostic 2015 Chagas disease
  • University of California San Diego (UCSD)
  • University of Washington (UW)
Collaboration to assess the efficacy of tuberculosis drugs using different delivery strategies 2014 Tuberculosis
  • Emory University
  • Northeastern University
  • University of Mauritius
Analyze the potential of Cameroonian fungi and medicinal plants for drugs development 2017 Buruli ulcer,Schistosomiasis,Leishmaniasis,Human African trypanosomiasis (HAT)
  • University of South Florida (USF)
  • University of Yaoundé I
Co-development and implementation of a bioinformatics course 2015 Malaria,Tuberculosis
  • University of Washington (UW)
  • Noguchi Memorial Institute for Medical Research (NMIMR)
Analyze of sequence variation of a P. falciparum red blood cell-binding protein within a set of malaria patient samples 2015 Malaria
  • Walter and Eliza Hall Institute of Medical Research (WEHI)
  • University Cheikh Anta Diop of Dakar (UCAD)
Inhibitors against Fasciola 2014 Onchocerciasis
  • Aberystwyth University
  • University of Buea
Activity against S. mansoni and S. haematobium or their intermediate snail hosts. 2018 Schistosomiasis
  • Griffith Institute for Drug Discovery (GRIDD)
  • University of Ibadan
Developing an antibody-based diagnostic device with the ability to detect adult stage O. volvulus. 2018 Onchocerciasis
  • University of British Columbia (UBC)
  • University of Buea
In vitro test of inhibitors for anti-parasitic drug discovery 2018 Leishmaniasis
  • Center for Infectious Disease Research (CIDR)
  • Takeda Pharmaceutical Company Limited
Synthesize an inhibitor against malaria parasites 2014 Malaria
  • McGill University
  • Northeastern University
Use of phage-display technology to develop new antibodies against chagas disease host biomarkers 2014 Chagas disease
  • McGill University
  • University of British Columbia (UBC)
Identification of hit inhibitors of critical parasitic metabolic pathways to develop drugs against HAT, leishmaniasis, and malaria 2018 Malaria,Leishmaniasis,Human African trypanosomiasis (HAT)
  • University of Yaoundé I
  • Johnson & Johnson
Jump-stARter library to screen against intracellular M. tuberculosis and Leishmania parasites 2017 Leishmaniasis,Tuberculosis
  • Infectious Disease Research Institute (IDRI)
  • Johnson & Johnson
Screen compounds against Onchocerca volvulus to identify potential drug candidates 2018 Onchocerciasis
  • Monash University
  • University of Melbourne
  • University of Buea
WIPO Fellowship - Research in Onchocerciasis (river blindness) 2013 Onchocerciasis
  • University of Buea
  • Novartis AG
WIPO Fellowship - Screening natural products sourced in Ghana against various parasites responsible for NTDs 2013 Lymphatic filariasis,Schistosomiasis,Chagas disease,Human African trypanosomiasis (HAT)
  • University of California San Francisco (UCSF)
  • University of Ghana
WIPO Fellowship - Screening plant extracts and compounds against schistosomiasis and other parasites 2015 Schistosomiasis,Leishmaniasis,Human African trypanosomiasis (HAT)
  • University of California San Diego (UCSD)
  • University of Ghana
WIPO Fellowship - Setting up different assays to find the best drug to treat tuberculosis 2013 Tuberculosis
  • AstraZeneca (Former Member)
  • South African Medical Research Council (SAMRC)
WIPO Fellowship - Probing the ubiquitination system as a target for developing new anti-malarials 2017 Malaria
  • University of Melbourne
  • International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)
WIPO Fellowship - Molecular surveillance and the development of genomic tools for malaria control 2017 Malaria
  • Walter and Eliza Hall Institute of Medical Research (WEHI)
  • Papua New Guinea Institute of Medical Research (PNGIMR)
WIPO Fellowship - Training in malaria drug discovery with emphasis on natural product drug discovery 2017 Malaria
  • Griffith Institute for Drug Discovery (GRIDD)
  • International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)
WIPO Fellowship - Testing the feasibility to use IR spectroscopy for the detection of antimalarial resistance 2018 Malaria
  • Monash University
  • National Institute for Medical Research (NIMR)
WIPO Fellowship - Identifying genetic biomarkers for disease susceptibility 2018 Dengue
  • Walter and Eliza Hall Institute of Medical Research (WEHI)
  • Eijkman Institute for Molecular Biology (EIMB)
WIPO Fellowship - Using system-wide approach to investigate the mechanisms of naturally acquired immunity against Malaria 2018 Malaria
  • Monash University
  • Kenya Medical Research Institute (KEMRI)
WIPO Fellowship - Identifying candidate targets for naturally acquired immunity for the design of novel anti-malarial vaccines 2018 Malaria
  • Walter and Eliza Hall Institute of Medical Research (WEHI)
  • Eijkman Institute for Molecular Biology (EIMB)
WIPO Fellowship - Identification of functional blocking antibody to inhibit the entry of the malarial parasite in red blood cells 2018 Malaria
  • Walter and Eliza Hall Institute of Medical Research (WEHI)
  • Bandung Institute of Technology (ITB)
WIPO Fellowship - Assessing the immunological correlates possibly associated with extrapulmonary dissemination of mycobacterium tuberculosis (Mtb) 2018 Tuberculosis
  • Walter and Eliza Hall Institute of Medical Research (WEHI)
  • Institut Pasteur de Madagascar (IPM)
Assay Support for Testing Lead Compounds for Activity Against a Specific Mycobacterium tuberculosis Target 2018 Tuberculosis
  • The George Washington University (GW)
  • MSD (Known as Merck & Co. Inc. in the United States of America and Canada)
Screening Dihydrofolate Reductase (DHFR) Inhibitors and Potassium Channel Blockers for HAT, Leishmaniasis, and Malaria Drug Discovery 2019 Malaria,Leishmaniasis,Human African trypanosomiasis (HAT)
  • University of Yaoundé I
  • Eisai Co., Ltd.
Screening the Jump-stARter Library for Antimalarial Drug Discovery 2018 Malaria
  • Washington University in St. Louis (WUSTL)
  • Johnson & Johnson
Ampli Blocks for Onchocerciasis Disgnostic Development 2018 Onchocerciasis
  • Massachusetts Institute of Technology (MIT)
  • University of Buea
Sharing of Artefenomel-like Trioxolane Analogs for Microsome Stability Testing 2018 Malaria
  • University of California San Francisco (UCSF)
  • Medicines for Malaria Venture (MMV)
Expertise Sharing for Alternate Administration of Antimalarial Candidate 2018 Malaria
  • The George Washington University (GW)
  • Washington University in St. Louis (WUSTL)
  • Pfizer Inc.
Identification of New Inhibitors of Trypanosoma cruzi Enzymes 2019 Chagas disease
  • Brazilian Biosciences National Laboratory (LNBio)
  • Novartis AG
Evaluation of Bactericidal Activity of TB47 Against Clinical M. Ulcerans Strains In Vitro 2019 Buruli ulcer
  • Guangzhou Institutes of Biomedicine and Health (GIBH)
  • Chinese Academy of Sciences
  • University of Yaoundé I
Sharing Compounds for Leishmaniasis Drug Discovery 2019 Leishmaniasis
  • Eisai Co., Ltd.
  • University of Texas (UT) Southwestern Medical Center
Screening TCAMS Library for Antimalarial Drug Discovery 2019 Malaria
  • Washington University in St. Louis (WUSTL)
  • GlaxoSmithKline (GSK)
Generating a Codon-Optimized Gene Construct to Aid SSGCID in their Structural Elucidation Efforts 2019 Schistosomiasis
  • MSD (Known as Merck & Co. Inc. in the United States of America and Canada)
  • Seattle Children's Research Institute (SCRI)
Screening of Merck KGaA, Darmstadt, Germany’s Mini Library for Buruli Ulcer Drug Discovery 2019 Buruli ulcer
  • University of Yaoundé I
  • Merck KGaA (Known as Merck KGaA, Darmstadt, Germany in the United States of America and Canada)
Screening of Merck KGaA, Darmstadt, Germany’s Mini Library for Chagas Disease, Human African Trypanosomiasis, and Leishmaniasis Drug Discovery 2020 Chagas disease,Leishmaniasis,Human African trypanosomiasis (HAT)
  • Griffith Institute for Drug Discovery (GRIDD)
  • Merck KGaA (Known as Merck KGaA, Darmstadt, Germany in the United States of America and Canada)
Screening of Phenotypic Library for Antimalarial Drug Discovery 2019 Malaria
  • Johnson & Johnson
  • Usmanu Danfodiyo University
  • Sokoto (UDUS)
Screening Jump-stARter Library Against Various Nematodes 2019 Soil-transmitted helminthiasis (STH)
  • University of Melbourne
  • Johnson & Johnson
Schistosomiasis Biomarker Validation and Proteomic Support 2020 Schistosomiasis
  • University of British Columbia (UBC)
  • University of Ibadan
Sharing of Phenotypic Library and Specific Compound Class For Snakebite Envenoming Drug Discovery 2019 Snakebite
  • Liverpool School of Tropical Medicine (LSTM)
  • Johnson & Johnson
Screening Jump-stARter Library for Leishmaniasis Drug Discovery 2020 Leishmaniasis
  • University of Washington (UW)
  • Johnson & Johnson
  • Seattle Children's Research Institute (SCRI)
Expression of Trypanosoma cruzi Topoisomerase II 2020 Chagas disease
  • Oswaldo Cruz Foundation (Fiocruz)
  • Seattle Children's Research Institute (SCRI)
Screening of Merck KGaA Mini Library for Leishmaniasis and Amoebiasis Drug Discovery 2020 Other - HIV, Chikungunya, Influenza, Zika,Leishmaniasis
  • University of Yaoundé I
  • Merck KGaA (Known as Merck KGaA, Darmstadt, Germany in the United States of America and Canada)
Screening Ghanaian Natural Product Extracts for Human African Trypanosomiasis (HAT) and Schistosomiasis Drug Discovery 2020 Schistosomiasis,Human African trypanosomiasis (HAT)
  • University of California San Diego (UCSD)
  • Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR)
Sharing Potassium Channel Blockers for Human African Trypanosomiasis, Leishmaniasis, and Malaria Drug Discovery 2021 Malaria,Leishmaniasis,Human African trypanosomiasis (HAT)
  • University of Yaoundé I
  • Pfizer Inc.
Screening Natural Products For Schistosomiasis Drug Discovery 2021 Schistosomiasis
  • University of California San Diego (UCSD)
  • University of Zambia
Crystallization of Potential Drug Targets for Kinetoplastid Diseases 2021 Chagas disease,Leishmaniasis,Human African trypanosomiasis (HAT)
  • Seattle Children's Research Institute (SCRI)
  • Institut Pasteur de Montevideo
Screening Pfizer Compounds for Antimalarial Drug Discovery 2021 Malaria
  • Pfizer Inc.
  • University of Tokyo
Screening of Open Global Health Library for Schistosomiasis Drug Discovery 2021 Schistosomiasis
  • Merck KGaA (Known as Merck KGaA, Darmstadt, Germany in the United States of America and Canada)
  • AHMADU BELLO UNIVERSITY ZARIA
Screening of African Natural Product Extracts for Antischistosomal Activity 2021 Schistosomiasis
  • Swiss Tropical and Public Health Institute (Swiss TPH)
  • Merck KGaA (Known as Merck KGaA, Darmstadt, Germany in the United States of America and Canada)
Screening of Open Global Health Library for Dengue Drug Discovery 2021 Dengue
  • Eijkman Institute for Molecular Biology (EIMB)
  • Merck KGaA (Known as Merck KGaA, Darmstadt, Germany in the United States of America and Canada)
Screening of Open Global Health Library for Snakebite Drug Discovery 2021 Snakebite
  • Liverpool School of Tropical Medicine (LSTM)
  • Merck KGaA (Known as Merck KGaA, Darmstadt, Germany in the United States of America and Canada)
Title Members
Expertise in schistosome developmental biology Aberystwyth University
Access to facilities for immunoprophylactic and chemotherapeutic studies of murine schistosomiasis Aberystwyth University
PBF is offering bacterial and viral purified protein production as well as live or killed vaccines. Aseptic filling , including live virus and bacteria,up to 2000 vials. Liquid, adjuvenated and lyophilization capability Walter Reed Army Institute of Research (WRAIR)
Codon harmonization patents as enabling technology for malaria and other diseases Walter Reed Army Institute of Research (WRAIR)
The Chemical Information System (CIS): USPO patent number 6,654,736 Walter Reed Army Institute of Research (WRAIR)
Dengue virus detection kit Walter Reed Army Institute of Research (WRAIR)
VMP001 Plasmodium vivax malaria vaccine antigens Walter Reed Army Institute of Research (WRAIR)
CelTOS Plasmodium falciparum malaria antigen Walter Reed Army Institute of Research (WRAIR)
Quantitative analysis from dried blood spots (Filter / PK) Walter Reed Army Institute of Research (WRAIR)
Veterinary Medicine Facility Walter Reed Army Institute of Research (WRAIR)
Tetravalent Purified-Inactivated Virus (TPIV) Vaccine for Dengue Walter Reed Army Institute of Research (WRAIR)
Clinical Trials Center Walter Reed Army Institute of Research (WRAIR)
SAGES: A A suite of freely-available software tools for electronic disease surveillance Walter Reed Army Institute of Research (WRAIR)
Methods for Synthesizing Vinyl Sulfones University of British Columbia (UBC)
Mycobacterial sulfation pathway proteins and methods of use thereof University of California, Berkeley (UCB)
Drug discovery capabilities for neglected tropical diseases Northeastern University
Collaboration in developing anti-tuberculosis compounds National University of Singapore (NUS)
Rapid Malaria detection diagnostic McGill University
Protein microarray for identifying bio-markers for potential use in malarial parasite diagnostics and vaccine development. National Institute of Parasitic Diseases (NIPD), Chinese Center for Disease Control and Prevention
Diagnostic tests for liver flukes National Institute of Parasitic Diseases (NIPD), Chinese Center for Disease Control and Prevention
New antigens for Malaria vaccine development and drug discovery University of Edinburgh
Novel compound series to treat African Trypanosomiasis University of Edinburgh
Formulation technology to protect vaccines from freeze damage PATH
Medicinal plants for onchocerciasis treatment University of Buea
Onchocerciasis and loaisis drug screening expertise and facilities University of Buea
Access to biological materials and field testing for onchocerciasis University of Buea
Availability of schistosome biological material Theodor Bilharz Research Institute (TBRI)
Expertise in drug discovery and evaluation of antischistosomal compounds/drugs Theodor Bilharz Research Institute (TBRI)
Testing of antischistosomal drugs Theodor Bilharz Research Institute (TBRI)
Prof. James (Jim) Heath, Caltech is providing expertise in designing more stable antibodies California Institute of Technology (Caltech)
Professor Brian Stoltz, Caltech is providing expertise to novel routes for pharmaceutical compound synthesis California Institute of Technology (Caltech)
Professor Axel Scherer, Caltech is providing expertise and knowledge sharing related to point of care diagnostics California Institute of Technology (Caltech)
Nanoparticles to enhance antibiotic delivery and performance University of South Florida (USF)
Quinolones having anti—malarial activity with reduced chemical resistance University of South Florida (USF)
Design and Immunogenicity of a Novel Synthetic Antigen of the Plasmodium vivax Duffy Binding Protein University of South Florida (USF)
Access to parasite repository University of South Florida (USF)
Tuberculosis R&D services University of Ibadan
Malaria and Soil-transmitted helminth infection diagnostic evaluation services University of Ibadan
Experience with medicinal plants in treatment of parasitic diseases University of Ibadan
Expertise in Schistosomiasis and Trypanosomiasis University of Ibadan
Experience with anti-helminthic drug clinical trial studies University of Ibadan
Access to DMPK platform African Institute of Biomedical Science and Technology (AiBST)
Biobank with African DNA samples African Institute of Biomedical Science and Technology (AiBST)
Drug Discovery and Development Capabilities: The Kansas University High Throughput Screening Center (HTS) University of Kansas
Drug discovery and development capabilities: The Macromolecule and Vaccine Stabilization Laboratory (MVSL) at Kansas University University of Kansas
Drug Discovery and Development Capabilities: The Institute for Advancing Medical Innovation (IAMI) at the University of Kansas University of Kansas
Drug Discovery and Development Capabilities: The Kansas University Biotechnology Innovation and Optimization Center (BIO Center) University of Kansas
Drug Discovery and Development Capabilities: The Kansas University Bioengineering Research Center (BERC) University of Kansas
Drug Discovery and Development Capabilities at University of Kansas University of Kansas
Nucleic acid construct for expressing vaccine antigens Pfizer Inc.
Moxidectin Pfizer Inc.
Selamectin Pfizer Inc.
Doramectin Pfizer Inc.
Espirantel Pfizer Inc.
Immunstimulatory CpG oligonucleotide vaccine adjuvant CpG10404 Pfizer Inc.
E3040 as dual 5-lipoxygenase and thromboxane A2 synthetase inhibitor Eisai Co., Ltd.
E4177: Selective Angiotensin II inhibitor Eisai Co., Ltd.
E5700 as squalene synthase inhibitor Eisai Co., Ltd.
E2011: Monoamine Oxidase a selective inhibitor Eisai Co., Ltd.
E4021 as type V phosphodiesterase (PDE) inhibitor Eisai Co., Ltd.
E4010 as phosphodiesterase type V inhibitor Eisai Co., Ltd.
E5510: Inhibitor of platelet agregation Eisai Co., Ltd.
Access to clinical trial sites for malaria, Human African Trypanosomiasis (HAT) and schistosomiasis University of Lagos (Unilag)
In vitro and in vivo platforms for screening crude plant extracts against parasitic agents University of Lagos (Unilag)
Access to malaria diagnostic evaluation University of Lagos (Unilag)
Malaria marker assessment services University of Lagos (Unilag)
Access to malaria biobank University of Lagos (Unilag)
Access to malaria diagnostics quality assurance services University of Lagos (Unilag)
Access to malaria slide bank for evaluation of Microscopy University of Lagos (Unilag)
TCAMS (Tres Cantos Antimalarial Set) GlaxoSmithKline (GSK)
Tres Cantos Open Lab GlaxoSmithKline (GSK)
GSK know-how from abandonned patents available for NTD research and development GlaxoSmithKline (GSK)
GSK patents (active) available for NTD research and development GlaxoSmithKline (GSK)
Patents around antibacterials and anti-tuberculosis GlaxoSmithKline (GSK)
WO 2003083068 Preparation of triazole derivatives as reversible inhibitors of bacterial methionine aminopeptidases, useful in treating bacterial infections GlaxoSmithKline (GSK)
WO 2002081415 Method for inhibiting methionine aminopeptidase type 2 (MetAP2), and inhibitor identification methods GlaxoSmithKline (GSK)
US 2005222212 Preparation of triazole derivatives as reversible inhibitors of bacterial methionine aminopeptidases, useful in treating bacterial infections GlaxoSmithKline (GSK)
Synthesis and biological assesment of anti-leishmania activity of modified 2-subsituted quinolines: DNDi data is made available herewith freely to third parties. Use of these data anywhere in the world is therefore not subject to any licensing terms. Drugs for Neglected Diseases initiative (DNDi)
Licochalcones analogues: DNDi data is made available herewith freely to third parties. Use of these data anywhere in the world is therefore not subject to any licensing terms. Drugs for Neglected Diseases initiative (DNDi)
Buparvquone analogues: DNDi data is made available herewith freely to third parties. Use of these data anywhere in the world is therefore not subject to any licensing terms. Drugs for Neglected Diseases initiative (DNDi)
Screening and optimization of specific chemical series against human African Trypanosomiasis (HAT): DNDi data is made available herewith freely to third parties. Use of these data anywhere in the world is therefore not subject to any licensing terms. Drugs for Neglected Diseases initiative (DNDi)
Optimisation of fenarimol series for the treatment of Chagas disease. DNDi data is made available herewith freely to third parties. Use of these data anywhere in the world is therefore not subject to any licensing terms. Drugs for Neglected Diseases initiative (DNDi)
Identification of compounds against Trypanosoma brucei brucei BS427 by high-throughput screening of whole parasites Drugs for Neglected Diseases initiative (DNDi)
Selection and optimisation of hits for the treatment of Chagas disease. DNDi data is made available herewith freely to third parties. Use of these data anywhere in the world is therefore not subject to any licensing terms. Drugs for Neglected Diseases initiative (DNDi)
Optimisation of fenarimol series for the treatment of Chagas disease (2nd release of data). DNDi data is made available herewith freely to third parties. Use of these data anywhere in the world is therefore not subject to any licensing terms. Drugs for Neglected Diseases initiative (DNDi)
Antiprotozoal activity profiling of approved drugs: a starting point toward drug repositioning. DNDi data is made available herewith freely to third parties. Use of these data anywhere in the world is therefore not subject to any licensing terms. Drugs for Neglected Diseases initiative (DNDi)
Development and Validation of a Novel Leishmania donovani Screening Cascade for High-Throughput Scrteening Using a Novel Axenic Assay with High Predictivity of Leishmanicidal Intracellular Activity. Drugs for Neglected Diseases initiative (DNDi)
Clinical trials facilities for parasitic diseases University of Bamako
New, cheaper production process for mefloquine hydrochloride anti-malaria drug Medicines for Malaria Venture (MMV)
Novartis-GNF Malaria Box Dataset (hits from P. falciparum whole-cell screening) Novartis AG
Novartis-GNF Anaerobic Mycobacterium tubeculosis (MTB) dataset (anaerobic MTB whole-cell screening) Novartis AG
Merck Long Chain Fatty Acyl Elongase (LCE) Inhibitors against protozoa MSD (Known as Merck & Co., Inc. in the United States of America and Canada)
Merck Casein Kinase I Inhibitors against Leishmaniasis MSD (Known as Merck & Co., Inc. in the United States of America and Canada)
Access to parasite bank Kenya Agricultural & Livestock Research Organisation (KALRO)
Infectra-kit vector and rodent holding apparatus for infection transmission experiments in the laboratory Kenya Agricultural & Livestock Research Organisation (KALRO)
Pre-clinical safety and toxicity testing and validation of test results in primate model Kenya Agricultural & Livestock Research Organisation (KALRO)
Natural Products and Bioaffinity Screening Griffith Institute for Drug Discovery (GRIDD)
Bioaffinity Mass Spectrometry Griffith Institute for Drug Discovery (GRIDD)
A Novel Treatment for Malarial Infections National Institutes of Health (NIH)
Chimeric And/Or Growth-Restricted Flaviviruses National Institutes of Health (NIH)
Trachoma vaccine National Institutes of Health (NIH)
C-terminally truncated dengue and Japanese encephalitis virus envelope proteins National Institutes of Health (NIH)
Dimeric Naphthylisoquinoline Alkaloids and Synthesis Methods Thereof National Institutes of Health (NIH)
Plasmodium Falciparum Gene Linked to Chloroquine Resistance in Human Malaria National Institutes of Health (NIH)
Novel Anti-Mycobacterial Compositions and Their Use for the Treatment of Tuberculosis and Related Diseases (2) National Institutes of Health (NIH)
Chondroitin sulphate A (CSA) binding domains National Institutes of Health (NIH)
Method to Create Vaccines for the Prevention of Flavivirus Infections by Targeting Micro-RNA National Institutes of Health (NIH)
Discovery of Novel Pharmacophores Inhibiting The Growth of Mycobacterium Tuberculosis (1) National Institutes of Health (NIH)
Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia Trachomatis National Institutes of Health (NIH)
Malarial Immunogen National Institutes of Health (NIH)
Antibodies Against the Amino Terminus Region of Circumsporozoite Protein Prevent the Onset of Malaria National Institutes of Health (NIH)
Infectious RNA transcribed from stable full-length CDNA of dengue type 4 virus National Institutes of Health (NIH)
Oligo Microarray for Detection of All Known Mammalian and Avian Pathogenic Viruses National Institutes of Health (NIH)
Attenuated Host-Range Restricted Dengue Viruses Derived by Site-Directed Mutagenesis of the Conserved 3-Stem and Loop Structure in Genomic RNA for Use as Vaccines National Institutes of Health (NIH)
Subgenomic replicons of the flavivirus dengue National Institutes of Health (NIH)
Growth- Restricted Dengue Type 4 Viruses and Vaccines Against The Same National Institutes of Health (NIH)
Discovery of Potential Antimalarial Drugs National Institutes of Health (NIH)
Generation of Wild-Type Dengue Viruses For Use In Rhesus Monkey Infection Studies National Institutes of Health (NIH)
Monoclonal Antibodies Against Dengue and Other Viruses With Deletion in Fc Region National Institutes of Health (NIH)
Intellectual property relating to vaccines for the prevention of transmission of leishmaniasis National Institutes of Health (NIH)
Chlamydia vaccine National Institutes of Health (NIH)
Circumsporozoite protein of Plasmodium Malariae National Institutes of Health (NIH)
Treatment of Schistosomiasis Using Substituted Oxadiazole 2-Oxides National Institutes of Health (NIH)
Monoclonal antibodies that bind or neutralize dengue virus National Institutes of Health (NIH)
Aspartic Protease Inhibitors National Institutes of Health (NIH)
The Use of Aerosolized Capreomycin for fhe Treatment of Pulmonary Tuberculosis National Institutes of Health (NIH)
Novel attenuated strains of mycobacterium tuberculosis National Institutes of Health (NIH)
Cysteine protease inhibitors for the treatment of Chagas disease and human African trypanosomiasis National Institutes of Health (NIH)
Multivalent Vaccines for Rabies Virus and Filoviruses National Institutes of Health (NIH)
Anti-Arthropod Vector Vaccines, Methods of Selecting, and Uses Thereof (1) National Institutes of Health (NIH)
Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia Trachomatis National Institutes of Health (NIH)
Target antigens of transmission blocking antibodies for Malaria parasites (2) National Institutes of Health (NIH)
Multiple Peptide Conjugates National Institutes of Health (NIH)
A Plasmid Containing A Hygromycin Resistance Cassette For Use In Construction of Transposons National Institutes of Health (NIH)
PFS25-28 Fusion as a Malaria Transmission Blocking Vaccine National Institutes of Health (NIH)
A series of Thalidomide analogs which exhibit inhibition of angiogenesis National Institutes of Health (NIH)
Synthetic Vaccine Against P. Falciparum Malaria National Institutes of Health (NIH)
Transmission blocking vaccine against malaria National Institutes of Health (NIH)
Haptoglobin Controls Blood Pressure Response To Plasma Free Hemoglobin: A Role Beyond Its Antioxidant Function National Institutes of Health (NIH)
Binding domains from plasmodium vivax and plasmodium falciparum erythrocyte binding proteins National Institutes of Health (NIH)
Anti-Plasmodium Antibodies And Methods of Use (2) National Institutes of Health (NIH)
Discovery of novel pharmacophores inhibiting the growth of Mycobacterium Tuberculosis (2) National Institutes of Health (NIH)
Vector for recombinant poxvirus expressing rabies virus glycoprotein National Institutes of Health (NIH)
Peptidomimetic inhibitors of cathepsin and plasmepsins I and II National Institutes of Health (NIH)
Antigenic Proteins of Plasmodium National Institutes of Health (NIH)
Monomeric and Dimeric Arylisoquinoline Alkaloids and Derivatives Thereof National Institutes of Health (NIH)
Antimalarial Naphthylisoquinoline Alkaloids and Pharmaceutical Compositions and Medical Uses Thereof National Institutes of Health (NIH)
Plasmodium Falciparum Erythrocyte Binding Protein Baebl For Use as a Vaccine National Institutes of Health (NIH)
Antimalarial korupensamines, and pharmaceutical compositions and medical uses thereof National Institutes of Health (NIH)
Expression, Purification And Efficacy testing of Synthetic Plasmodium Falciparum Apical Membrane Antigen 1 Expressed in Pichia Pastoris National Institutes of Health (NIH)
Identification of a Region of Merozoite Surface Protein 1 (MSP-1) Necessary for Protective Immunity National Institutes of Health (NIH)
Synthetic Genes For Malarial Proteins And Methods of Use National Institutes of Health (NIH)
Anti-Plasmodium Compositions And Methods of Use (1) National Institutes of Health (NIH)
Lymphatic Filariasis-Prepatent Stage Diagnostic National Institutes of Health (NIH)
Inhibition of Human Immunodeficiency Virus -1 Infectivity In Human Cells National Institutes of Health (NIH)
A multi-component vaccine for Malaria providing long-lasting immune responses against Plasmodia (1) National Institutes of Health (NIH)
Anti-mycobacterial compositions and their use for the treatment of tuberculosis and related diseases (1) National Institutes of Health (NIH)
Plasmodium vivax and plasmodium knowlesi duffy receptor National Institutes of Health (NIH)
Pvs28, a vaccine candidate for blocking transmission of plasmodium vivax National Institutes of Health (NIH)
Oligo- or poly a (1-2)-D-Glucose-based vaccine for prevention and for treatment of tuberculosis National Institutes of Health (NIH)
Recombinant DNA Clone Containing A Genomic Fragment of PFHRP-II Gene From Plasmodium Falciparum National Institutes of Health (NIH)
Monoclonal Antibodies Which Block Infectivity of Malarial Parasites to Mosquitoes National Institutes of Health (NIH)
Target antigens of transmission blocking antibodies for Malaria parasites (1) National Institutes of Health (NIH)
Vaccine designed for long-lasting and transmission-blocking activity of antibodies to Plasmodium Falciparum Elicited in Mice by protein conjugates of PFs25 National Institutes of Health (NIH)
A Novel Monoclonal Antibody For Use As A TB Specific Diagnostic Tool For Detecting Humans Infected With TB And Other Related Pathogens And For Use In Research On The Imunopathogenesis of M. Tuberculosis National Institutes of Health (NIH)
Immunologically Active Peptides Capable of Inducing Immunization Against Malaria And Genes Encoding Therefor National Institutes of Health (NIH)
Protective Synthetic Peptide Against Malaria And Encoding Gene National Institutes of Health (NIH)
Collagen-platelet Aggregation Inhibitor From Mosquito Salivary Glands National Institutes of Health (NIH)
A Multicomponent Vaccine For Malaria Providing Long-lasting Immune Responses Against Plasmodia (2) National Institutes of Health (NIH)
Anti-Arthropod Vector Vaccines, Methods of Selecting, and Uses Thereof (2) National Institutes of Health (NIH)
Lateral Flow Assay Device for Rapid Diagnostic of Cutaneous Leishmaniasis (LAFALE [lateral flow assay for leishmaniasis] platform) Universidad Peruana Cayetano Heredia